Accepted for/Published in: JMIR Research Protocols
Date Submitted: Feb 4, 2020
Date Accepted: Jun 2, 2020
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Comparing Conventional Chemotherapy to Chronomodulated Chemotherapy for Cancer Treatment: A Systematic Review Protocol
ABSTRACT
Background:
Chronomodulated chemotherapy aims to achieve maximum drug safety and efficacy through adjusting the time of treatment to the optimal biological time as determined by the circadian body clock. Although it has in several instances been found to be a promising alternative to conventional (untimed) chemotherapy, the lack of scientific consensus and increased logistical burden of timed administration causes a limited use of chronomodulated administration protocols.
Objective:
With the goal to increase scientific consensus about this subject, we plan to conduct a systematic review of the current literature to compare the drug safety and efficacy of chronomodulated chemotherapy versus conventional chemotherapy.
Methods:
This systematic review will comply with the Preferred Reporting Items for the Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Electronic searches of reviews and randomized clinical trials written in English will be conducted on PubMed from inception to 2019, EMBASE from inception to 2019 and Scopus from 2014-2019 (Table 1). We will include studies that compare the safety and efficacy (ie, patient survival) of chronomodulated chemotherapy versus conventional chemotherapy. Two reviewers will independently review and screen potential studies. Quality assessment will be assessed with the NIH Study Quality Assessment Tool (Quality Assessment of Controlled Intervention Studies). Disagreements will be resolved by consulting a third independent reviewer.
Results:
This protocol has received funding and the search for studies from databases will commence in February 2020. The systematic review is planned to be completed in June 2020.
Conclusions:
In this systematic review, we will compare drug safety, drug efficacy of cancer patients administered either chronomodulated chemotherapy or conventional chemotherapy. Moreover, we will highlight the outcomes and quality of the selected trials for this review. Clinical Trial: International Prospective Register for Systematic Reviews (PROSPERO) number CRD42019118218.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.